Research and Markets (http://www.researchandmarkets.com/research/n5mgsx/zimbabwe_pharmaceu)
has announced the addition of the "Zimbabwe
Pharmaceuticals and Healthcare Report Q2 2012" report to their
On account of its unpredictable and unfavourable operating environment
and limited funding for and investment in healthcare and medicines,
Zimbabwe's pharmaceutical market will remain unattractive to foreign
companies for the foreseeable future. Poor healthcare provision and
coverage will continue to provide further operating challenges, as most
of the population struggles to afford basic medicines, which also
largely have to be sourced with out-of-pocket spending.
Headline Expenditure Projections
-Pharmaceuticals: US$160mn in 2011 to US$181mn in 2012; 13.5% in US
dollar terms. Forecast unchanged from Q112.
-Healthcare US$833mn in 2011 to US$919mn in 2012; 10.3% in US dollar
terms. Forecast broadly unchanged from Q112.
-Medical devices: US$44mn in 2011 to US$50mn in 2012; 12.6% in US dollar
terms. Forecast unchanged from Q112.
Key Trends And Developments
CAPS Holdings, a Zimbabwean company with subsidiaries in all verticals
of healthcare delivery in the country, has seen things turn from bad to
worse in recent months. In November 2011, the company's largest
shareholder, Frederick Mtandah, and general manager Justice Majaka were
arrested by the Anti-Corruption Commission (ACC) for fraud. They have
both since been cleared of wrongdoing, though the prosecution may still
push for a retrial in early 2012. BMI Economic View: Tight domestic and
regional food supplies and the introduction of a surcharge on a range of
manufactured goods will drive headline inflation higher in Zimbabwe in
2012, which will negatively affect the availability of out-of-pocket
finances for healthcare and pharmaceuticals. The author has forecast a
relatively gradual increase to 7.5% by the end of 2012, with an average
of 6.1% for the year.
For more information visit http://www.researchandmarkets.com/research/n5mgsx/zimbabwe_pharmaceu